LAVAL, Quebec, Jan. 25, 2016 /CNW/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today
released a memo sent to Valeant employees from J. Michael Pearson, who is currently out on
medical leave.
The full text of the memo to employees is as follows:
Dear Colleagues;
I want to thank everyone for the outpouring of support and well
wishes you have expressed over the past few weeks. As you know, I
unexpectedly entered the hospital in late December to receive
treatment for severe pneumonia and some unexpected complications
resulted in a longer hospital stay than anticipated. I'm glad
to say that I'm on the road to recovery and although the timing of
my return remains uncertain, I look forward to being back at work
when able.
I would like to thank all of you for the hard work and diligence
you have demonstrated during my absence by continuing to deliver
important medicines and products to the doctors and patients who
need them. I specifically want to thank Howard for stepping in as
Interim CEO and to all the members of the management team for the
leadership that they have shown. While the past few months
have been difficult, I am convinced we will emerge stronger than
ever and our future remains bright.
With best regards,
Mike
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorder,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements,
including, but not limited to, statements regarding the health of
J. Michael Pearson and his expected
return to the Company. Forward-looking statements may
generally be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"will," "believes," "estimates," "potential," "target," or
"continue" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties discussed in the
Company's most recent annual or quarterly report and detailed from
time to time in Valeant's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Valeant undertakes no obligation to
update any of these forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
actual outcomes, unless required by law.
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
Elif McDonald
905-695-7607
elif.mcdonald@valeant.com
Media:
Renée E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-provides-update-on-j-michael-pearson-300208843.html
SOURCE Valeant Pharmaceuticals International, Inc.